.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Federal Trade Commission
Cipla
Argus Health
Boehringer Ingelheim
Deloitte
McKinsey
US Department of Justice
Fish and Richardson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Arbor Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ARBOR PHARMS LLC, and when can generic versions of ARBOR PHARMS LLC drugs launch?

ARBOR PHARMS LLC has twenty-one approved drugs.

There are nineteen US patents protecting ARBOR PHARMS LLC drugs on ARBOR PHARMS LLC drugs in the past three years.

There are two hundred and sixty-eight patent family members on ARBOR PHARMS LLC drugs in forty-two countries and twenty-six supplementary protection certificates in fourteen countries.

Summary for Arbor Pharms Llc

International Patents:268
US Patents:19
Tradenames:22
Ingredients:14
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms LlcSOTYLIZEsotalol hydrochlorideSOLUTION;ORAL205108-001Oct 22, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Arbor Pharms LlcERYTHROMYCINerythromycinTABLET;ORAL061621-001Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcPCEerythromycinTABLET, COATED PARTICLES;ORAL050611-001Sep 9, 1986RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcPCEerythromycinTABLET, COATED PARTICLES;ORAL050611-002Aug 22, 1990RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-001Feb 25, 2011RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Arbor Pharms LlcE.E.S. 200erythromycin ethylsuccinateSUSPENSION;ORAL061639-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcERYTHROMYCINerythromycinTABLET;ORAL061621-002Approved Prior to Jan 1, 1982RXNoYes► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcERY-TABerythromycinTABLET, DELAYED RELEASE;ORAL062298-003Mar 29, 1982RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Arbor Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-002Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-002Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBYCLORazilsartan kamedoxomil; chlorthalidoneTABLET;ORAL202331-002Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms LlcGLIADELcarmustineIMPLANT;INTRACRANIAL020637-001Sep 23, 1996► Subscribe► Subscribe
Arbor Pharms LlcEDARBYCLORazilsartan kamedoxomil; chlorthalidoneTABLET;ORAL202331-001Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBYCLORazilsartan kamedoxomil; chlorthalidoneTABLET;ORAL202331-001Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBYCLORazilsartan kamedoxomil; chlorthalidoneTABLET;ORAL202331-002Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms LlcEDARBIazilsartan kamedoxomilTABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ARBOR PHARMS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
ivermectinLotion0.5%SKLICE9/1/2017

Non-Orange Book Patents for Arbor Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,168,623Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
9,150,503Crystalline form of .gamma.-aminobutyric acid analog► Subscribe
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity► Subscribe
8,906,412GABA analog prodrug sustained release oral dosage forms► Subscribe
8,367,722Methods of using prodrugs of pregabalin► Subscribe
9,238,616Prodrugs of gaba analogs, compositions and uses thereof► Subscribe
7,790,708Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
7,232,924Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
7,875,637Benzimidazole derivative and use as a II receptor antagonist► Subscribe
7,423,169Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Arbor Pharms Llc Drugs

Country Document Number Estimated Expiration
Singapore147437► Subscribe
Austria540678► Subscribe
TaiwanI474841► Subscribe
MexicoPA06004088► Subscribe
Canada2681143► Subscribe
European Patent Office1857457► Subscribe
Israel200687► Subscribe
Serbia52376► Subscribe
South Korea20040016882► Subscribe
Israel210819► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Arbor Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6Finland► Subscribe
2015033Lithuania► SubscribePRODUCT NAME: IVERMECTINUM; NAT. REGISTRATION NO/DATE: LT/1/15/3726/001 - LT/1/15/3726/005 20150513; FIRST REGISTRATION: MA117/01101 20150402
2015000079Germany► SubscribePRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402
90036Netherlands► SubscribePRODUCT NAME: CARMUSTINE; NAT. REGISTRATION NO/DATE: RVG 24056 19990809; FIRST REGISTRATION: FR 561 907-5 19981210
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
2012 00013Denmark► Subscribe
962Luxembourg► Subscribe91962, EXPIRES: 20261207
915Luxembourg► SubscribePRODUCT NAME: IVERMECTINE POUR SON USAGE DANS LE TRAITEMENT DE LA ROSACEA; FIRST REGISTRATION: 20150402
90016-3Sweden► SubscribePRODUCT NAME: AZILSARTANMEDOXOMIL OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV, INKLUDERANDE KALIUMSALT; REG. NO/DATE: EU/1/11/735/001 20111207
/2015Austria► SubscribePRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
US Department of Justice
UBS
Chubb
Healthtrust
Farmers Insurance
Baxter
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot